Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Robinson, Prema ^a   Kasembeli, Moses ^a   Bharadwaj, Uddalak ^a   Engineer, Nikita ^b   Eckols, Kris T ^a   Tweardy, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LEE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DOXORUBICIN; NEUROKININ 1 RECEPTOR; REACTIVE OXYGEN METABOLITE; SUBSTANCE P ANTAGONIST; MORPHOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CARDIOTOXICITY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CARDIAC MUSCLE CELL; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; RAT; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARDIOTOXICITY; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MORPHOLINES; MYOCYTES, CARDIAC; RATS; RECEPTORS, NEUROKININ-1; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84959254965     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/1959270     Document Type: Article

References (49)

1. B. K. Sinha, E. G. Mimnaugh, S. Rajagopalan, and C. E. Myers, "Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in Adriamycin resistance," Cancer Research, vol. 49, no. 14, pp. 3844-3848, 1989.
2. P. Tassone, P. Tagliaferri, A. Perricelli et al., "BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells," British Journal of Cancer, vol. 88, no. 8, pp. 1285-1291, 2003.
3. G. Curigliano, D. Cardinale, T. Suter et al., "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines," Annals of Oncology, vol. 23, supplement 7, Article ID mds293, pp. vii155-vii166, 2012.
4. E. T. H. Yeh, A. T. Tong, D. J. Lenihan et al., "Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management," Circulation, vol. 109, no. 25, pp. 3122-3131, 2004.
5. L. A. Smith, V. R. Cornelius, C. J. Plummer et al., "Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials," BMC Cancer, vol. 10, article 337, 2010.
6. D. D. Von Hoff, M. W. Layard, P. Basa et al., "Risk factors for doxorubicin-induced congestive heart failure," Annals of Internal Medicine, vol. 91, no. 5, pp. 710-717, 1979.
7. F. Andre and C. C. Zielinski, "Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents," Annals of Oncology, vol. 23, supplement 6, pp. vi46-vi51, 2012.
8. G. von Minckwitz and M. Martin, "Neoadjuvant treatments for triple-negative breast cancer (TNBC)," Annals of Oncology, vol. 23, supplement 6, pp. vi35-vi39, 2012.
9. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015," CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
10. E. M. Ward, C. E. DeSantis, C. C. Lin et al., "Cancer statistics: breast cancer in situ," CA: A Cancer Journal for Clinicians, vol. 65, no. 6, pp. 481-495, 2015.
11. P. Honore, S. D. Rogers, M. J. Schwei et al., "Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons," Neuroscience, vol. 98, no. 3, pp. 585-598, 2000.
12. J. V. Weinstock, A. Blum, J. Walder, and R. Walder, "Eosinophils from granulomas in murine schistosomiasis mansoni produce substance P.," The Journal of Immunology, vol. 141, no. 3, pp. 961-966, 1988.
13. C. A. Maggi, "The effects of tachykinins on inflammatory and immune cells," Regulatory Peptides, vol. 70, no. 2-3, pp. 75-90, 1997.
14. W.-Z. Ho, J.-P. Lai, X.-H. Zhu, M. Uvaydova, and S. D. Douglas, "Human monocytes and macrophages express substance P and neurokinin-1 receptor," The Journal of Immunology, vol. 159, no. 11, pp. 5654-5660, 1997.
15. D. J. Church, S. J. Arkinstall, M. B. Vallotton, A. Chollet, E. Kawashima, and U. Lang, "Stimulation of atrial natriuretic peptide release by neurokinins in neonatal rat ventricular cardiomyocytes," American Journal of Physiology - Heart and Circulatory Physiology, vol. 270, no. 3, part 2, pp. H935-H944, 1996.
16. T. Goode, J. O'Connell, C. Sternini et al., "Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononulear cells: molecular quantitation and localization," The Journal of Immunology, vol. 161, no. 5, pp. 2232-2240, 1998.
17. G. A. Cook, D. Elliott, A. Metwali et al., "Molecular evidence that granuloma T lymphocytes in murine Schistosomiasis mansoni express an authentic substance P (NK-1) receptor," Journal of Immunology, vol. 152, no. 4, pp. 1830-1835, 1994.
18. M. I. Tejero-Taldo, J. H. Kramer, I. T. Mak, A. M. Komarov, and W. B. Weglicki, "The nerve-heart connection in the pro-oxidant response to Mg-deficiency," Heart Failure Reviews, vol. 11, no. 1, pp. 35-44, 2006.
19. A. Sterner-Kock, R. K. Braun, A. van der Vliet et al., "Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils," Journal of Leukocyte Biology, vol. 65, no. 6, pp. 834-840, 1999.
20. K. Chen and J. F. Keaney Jr., "Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease," Current Atherosclerosis Reports, vol. 14, no. 5, pp. 476-483, 2012.
21. K. Sugamura and J. F. Keaney Jr., "Reactive oxygen species in cardiovascular disease," Free Radical Biology and Medicine, vol. 51, no. 5, pp. 978-992, 2011.
22. P. Robinson, A. Garza, J. Moore et al., "Substance P is required for the pathogenesis of EMCV infection in mice," International Journal of Clinical and Experimental Medicine, vol. 2, no. 1, pp. 76-86, 2009.
23. G. C. Melendez, J. Li, B. A. Law, J. S. Janicki, S. C. Supowit, and S. P. Levick, "Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells," Cardiovascular Research, vol. 92, no. 3, pp. 420-429, 2011.
24. W. B. Weglicki, I. T. Mak, and T. M. Phillips, "Blockade of cardiac inflammation in Mg2+ deficiency by substance P receptor inhibition," Circulation Research, vol. 74, no. 5, pp. 1009-1013, 1994.
25. I. T. Mak, J. J. Chmielinska, J. H. Kramer, C. F. Spurney, and W. B. Weglicki, "Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: protection by substance P receptor blockade," Experimental and Clinical Cardiology, vol. 16, no. 4, pp. 121-124, 2011.
26. M. Munoz, M. Rosso, and R. Covenas, "A new frontier in the treatment of cancer: NK-1 receptor antagonists," Current Medicinal Chemistry, vol. 17, no. 6, pp. 504-516, 2010.
27. M. Munoz, M. Rosso, and R. Covenas, "The NK-1 receptor: a new target in cancer therapy," Current Drug Targets, vol. 12, no. 6, pp. 909-921, 2011.
28. I. M. Hennig, J. A. Laissue, U. Horisberger, and J.-C. Reubi, "Substance-P receptors in human primary neoplasms: tumoral and vascular localization," International Journal of Cancer, vol. 61, no. 6, pp. 786-792, 1995.
29. K. A. DeFea, Z. D. Vaughn, E. M. O'Bryan, D. Nishijima, O. Dery, and N. W. Bunnett, "The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex," Proceedings of the National Academy of Sciences, vol. 97, no. 20, pp. 11086-11091, 2000.
30. F. Feng, J. Yang, L. Tong et al., "Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells," Cell Biology International, vol. 35, no. 6, pp. 623-629, 2011.
31. K. M. Lewis, E. Harford-Wright, R. Vink, A. J. Nimmo, and M. N. Ghabriel, "Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion," Clinical & Experimental Metastasis, vol. 30, no. 1, pp. 1-12, 2013.
32. S. L. Fink and B. T. Cookson, "Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells," Infection and Immunity, vol. 73, no. 4, pp. 1907-1916, 2005.
33. Y.-Y. Park, S. Y. Jung, N. B. Jennings et al., "FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair," Carcinogenesis, vol. 33, no. 10, pp. 1843-1853, 2012.
34. S. Zhang, X. Liu, T. Bawa-Khalfe et al., "Identification of the molecular basis of doxorubicin-induced cardiotoxicity," Nature Medicine, vol. 18, no. 11, pp. 1639-1642, 2012.
35. S. C. Huelsenbeck, A. Schorr, W. P. Roos et al., "Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons," Journal of Biological Chemistry, vol. 287, no. 46, pp. 38590-38599, 2012.
36. S. O. Kim, K. Ono, P. S. Tobias, and J. Han, "Orphan nuclear receptor Nur77 is involved in caspase-independent macrophage cell death," The Journal of Experimental Medicine, vol. 197, no. 11, pp. 1441-1452, 2003.
37. S. Castro-Obregón, R. V. Rao, G. del Rio et al., "Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77," Journal of Biological Chemistry, vol. 279, no. 17, pp. 17543-17553, 2004.
38. H. Bhanot, A. M. Young, J. H. Overmeyer, and W. A. Maltese, "Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6," Molecular Cancer Research, vol. 8, no. 10, pp. 1358-1374, 2010.
39. J.-Y. Byun, C.-H. Yoon, S. An et al., "The Rac1/MKK7/JNK pathway signals upregulation of Atg5 and subsequent autophagic cell death in response to oncogenic Ras," Carcinogenesis, vol. 30, no. 11, pp. 1880-1888, 2009.
40. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor, "Programmed death-1 pathway in cancer and autoimmunity," Clinical Immunology, vol. 153, no. 1, pp. 145-152, 2014.
41. A. E. Yesilkanal and M. R. Rosner, "Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer," Critical Reviews in Oncogenesis, vol. 19, no. 6, pp. 447-454, 2014.
42. H. Friess, Z. Zhu, V. Liard et al., "Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer," Laboratory Investigation, vol. 83, no. 5, pp. 731-742, 2003.
43. 11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer," Cancer Research, vol. 65, no. 7, pp. 2738-2745, 2005.
44. M. Muñoz and M. Rosso, "The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug," Investigational New Drugs, vol. 28, no. 2, pp. 187-193, 2010.
45. X. Li, G. Ma, Q. Ma et al., "Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells," Molecular Cancer Research, vol. 11, no. 3, pp. 294-302, 2013.
46. Y. Zhou, L. Zhao, T. Xiong et al., "Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer," Breast Cancer Research and Treatment, vol. 140, no. 1, pp. 49-61, 2013.
47. D. Singh, D. D. Joshi, M. Hameed et al., "Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 1, pp. 388-393, 2000.
48. M. Munoz, A. Gonzalez-Ortega, M. V. Salinas-Martin et al., "The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer," International Journal of Oncology, vol. 45, no. 4, pp. 1658-1672, 2014.
49. M. Berger, O. Neth, M. Ilmer et al., "Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo," Journal of Hepatology, vol. 60, no. 5, pp. 985-994, 2014.